臨床検査54巻13号

2010年12月発行

今月の主題 遺伝子検査の最近の展開－ヒトゲノム多様性と医療応用 各論

肺癌の遺伝子検査

著者： 福原達朗¹ 井上彰¹ 貫和敏博¹

所属機関： ¹東北大学病院呼吸器内科

ページ範囲：P.1649 - P.1654

　肺癌は依然として日本における最も死亡者数の多い悪性腫瘍である．上皮増殖因子受容体(EGFR)の遺伝子変異陽性の肺癌に対して，EGFR阻害剤であるゲフィチニブ，エルロチニブの治療効果が明らかとなりつつある．特に最近日本より第3相臨床試験の結果が相次いで報告され，新たなエビデンスが築かれた．新規融合遺伝子EML4-ALKは肺癌で発見され，ALK阻害剤は新たな分子標的治療の手段となる可能性がある．このように肺癌に対しての個別化治療への研究と臨床応用が少しずつ進められている．

参考文献

1) Lynch TJ, Bell DW, Sordella R, et al:Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med　350：2129-2139，2004

2) Paez JG, Janne PA, Lee JC, et al:EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science　304：1497-1500，2004

3) Mok TS, Wu YL, Thongprasert S, et al:Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med　361：947-957，2009

4) Inoue A, Suzuki T, Fukuhara T, et al:Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol　24：3340-3346，2006

5) Asahina H, Yamazaki K, Kinoshita I, et al:A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer　95：998-1004，2006

6) Sutani A, Nagai Y, Udagawa K, et al:Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer　95：1483-1489，2006

7) Mitsudomi T, Morita S, Yatabe Y, et al:Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol　11：121-128，2010

8) Maemondo M, Inoue A, Kobayashi K, et al:Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med　362：2380-2388，2010

9) Sunaga N, Tomizawa Y, Yanagitani N, et al:Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer　56：383-389，2007

10) Yoshida K, Yatabe Y, Park JY, et al:Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol　2：22-28，2007

11) Inoue A, Kobayashi K, Usui K, et al:First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol　27：1394-1400，2009

12) Ji H, Li D, Chen L, et al:The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell　9：485-495，2006

13) Bell DW, Gore I, Okimoto RA, et al:Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet　37：1315-1316，2005

14) Zhou W, Ercan D, Chen L, et al:Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature　462：1070-1074，2009

15) Engelman JA, Zejnullahu K, Mitsudomi T, et al:MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science　316：1039-1043，2007

16) Sharma SV, Lee DY, Li B, et al:A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell　141：69-80，2010

17) Cho BC, Im CK, Park MS, et al:Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol　25：2528-2533，2007

18) Nagai Y, Miyazawa H, Huqun, et al:Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res　65：7276-7282，2005

19) Soda M, Choi YL, Enomoto M, et al:Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature　448：561-566，2007

20) Soda M, Inoue A, Isobe K, et al:A Japanese nation-wide network for the diagnosis of EML4-ALK-positive lung cancer;a joint study of ALCAS and NEJ004. J Clin Oncol 28(Suppl)：abstr 10534，2010

21) Bang Y, Kwak EL, Shaw AT, et al:Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28(Suppl)：abstr 3，2010

22) Inoue A, Saijo Y, Maemondo M, et al:Severe acute interstitial pneumonia and gefitinib. Lancet　361：137-139，2003

23) Pleasance ED, Stephens PJ, O'Meara S, et al:A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature　463：184-190，2010

24) Lee W, Jiang Z, Liu J, et al:The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature　465：473-477，2010

25) Kan Z, Jaiswal BS, Stinson J, et al:Diverse somatic mutation patterns and pathway alterations in human cancers. Nature　466：869-873，2010